Table IV.
Risk factors for venous thromboembolism (VTE) development during the follow-up period
| STENOX, 200319 | Decousus et al (POST), 20105 | Galanaud et al (Optimev), 20116 | Cosmi et al (STEFLUX), 201224, 40 | Barco S et al (ICARO), 201732 | Blin et al, 201731 | Geersing et al, 20183 | Casian D et al, 202237 | Karathanos C et al (SeVEN), 202335 | Rabe E et al (INSIGHTS-SVT), 202338 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Male sex | 2.2 (1.3-3.7) | 2.6 (1.4-4.9) | 3.5 (1.1-11.3) | 2.0 (1.2-3.5) | ||||||
| Cancer | 3.1 (1.2-8.5) | 3.1 (1.1-8.9) | 2.2 (0.9-4.9) | |||||||
| Inpatient treatment | 4.5 (1.3-15.3) | |||||||||
| History of VTE | 2.1 (1.1-4.0) | 2.2 (1.2-4.1) | 2.1 (1.3-3.2) | 2.5 (1.1-6.1) | 2.9 (1.5-5.6) | |||||
| Non-varicose veins | 2.1 (1.1-4.3) | 2.6 (1.3-5.0) | 1.8 (1.0-2.9) | |||||||
| Symptoms <7 days | 3.0 (1.4-6.3) | |||||||||
| Progressive stage of CVD | 2.8 (1.1-6.9) | |||||||||
| Increased BMI | 2.2 (1.3-3.2) | 1.06 (1.02-1.11) | ||||||||
| Thrombus <3 cm of junction | 2.5 (1.1-6.1) | |||||||||
| Thrombus length | 1.02 (1.0-1.05) | |||||||||
| Chronic- reduced mobility | 4.6 (1.5-14.2) | |||||||||
| Severe systemic infection | 7.6 (1.8-32.5) |
BMI, Body mass index; CVD, chronic venous disease (progressive CVD means stage 3 by Porter);
BMI increased means more than 25 kg/m2.
Cancer combines active and historical.
History of VTE combines personal and family history of superficial vein thrombosis, deep vein thrombosis, and pulmonary embolism.
Thrombus length reported as hazard ratio for every 1 cm.
Data are presented as the odds ratios or hazard ratios (with 95% confidence interval).